Separate terms with OR to return results that match either term.
 
Clear All
700 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class (Descending) Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Vandetanib Caprelsa 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Axitinib Axitinib 5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cometriq 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cabometyx 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cabometyx 60 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
Q2024 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Oct. 1, 2009 Dec. 31, 2009 No Longer Used
C9257 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan. 1, 2010 In Use
C9214 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Feb. 26, 2004 Dec. 31, 2004 No Longer Used
J9035 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan. 1, 2005 In Use
S0116 Bevacizumab Avastin 100 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 July 1, 2004 June 30, 2006 No Longer Used
C9025 Ramucirumab Cyramza 5 mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Oct. 1, 2014 Dec. 31, 2015 No Longer Used
J9308 Ramucirumab Cyramza 5mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Jan. 1, 2016 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct. 1, 2019 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
Q5107 Bevacizumab-awwb Mvasi 10mg Immunotherapy Monoclonal Antibody VEGFR No 2018 Jan. 1, 2019 In Use
Q5129 Bevacizumab-adcd Vegzelma 10mg Immunotherapy Monoclonal Antibody VEGFR No 2023 March 17, 2023 In Use
C9296 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan. 1, 2013 Dec. 31, 2013 No Longer Used
J9400 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan. 1, 2014 In Use
C9142 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Sept. 27, 2022 Dec. 21, 2022 No Longer Used
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov. 28, 2022 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use

Found 700 results in 1 millisecond — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.